Herve Puy

List of Publications by Year in Descending Order

142 papers	5,727 citations	40 h-index	71 g-index
156 ext. papers	6,723 ext. citations	7.2 avg, IF	5.24 L-index

#	Paper	IF	Citations
142	Iron, Heme Synthesis and Erythropoietic Porphyrias: A Complex Interplay.. *Metabolites*, **2021**, 11,	5.6	1
141	Identification of novel mutations in a patient with congenital erythropoietic porphyria and efficient treatment by phlebotomy. *Molecular Genetics and Metabolism Reports*, **2021**, 27, 100722	1.8	3
140	Hepcidin and Iron Deficiency in Women One Year after Sleeve Gastrectomy: A Prospective Cohort Study. *Nutrients*, **2021**, 13,	6.7	1
139	Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria. *Haematologica*, **2021**, 106, 913-917	6.6	7
138	A mutation in the iron-responsive element of is a modifier of disease severity in a patient suffering from associated erythropoietic protoporphyria. *Haematologica*, **2021**, 106, 2030-2033	6.6	2
137	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. *Bioanalysis*, **2021**, 13, 1029-1035	2.1	2
136	Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1). *Kidney International Reports*, **2021**, 6, 1904-1911	4.1	6
135	TSPO2 translocates 5-aminolevulinic acid into human erythroleukemia cells. *Biology of the Cell*, **2020**, 112, 113-126	3.5	2
134	Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. *Blood*, **2020**, 136, 2457-2468	2.2	9
133	Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. *Molecular Genetics and Metabolism*, **2020**, 131, 259-266	3.7	3
132	GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia. *Molecular Genetics and Metabolism*, **2019**, 128, 342-351	3.7	9
131	Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyria. *American Journal of Human Genetics*, **2019**, 104, 341-347	11	17
130	Regulation of globin-heme balance in Diamond-Blackfan anemia by HSP70/GATA1. *Blood*, **2019**, 133, 1358-1370	2.2	21
129	International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias. *Genetics in Medicine*, **2019**, 21, 2605-2613	8.1	11
128	Regulation and tissue-specific expression of □aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias. *Molecular Genetics and Metabolism*, **2019**, 128, 190-197	3.7	13
127	Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. *Molecular Genetics and Metabolism*, **2019**, 128, 309-313	3.7	7
126	A variant erythroferrone disrupts iron homeostasis in -mutated myelodysplastic syndrome. *Science Translational Medicine*, **2019**, 11,	17.5	27

125	Genetic background influences hepcidin response to iron imbalance in a mouse model of hemolytic anemia (Congenital erythropoietic porphyria). *Biochemical and Biophysical Research Communications*, **2019**, 520, 297-303	3.4	3
124	Extrahepatic hepcidin production: The intriguing outcomes of recent years. *World Journal of Clinical Cases*, **2019**, 7, 1926-1936	1.6	6
123	Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients. *Nephrology*, **2019**, 24, 751-757	2.2	3
122	Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. *Molecular Genetics and Metabolism*, **2019**, 128, 236-241	3.7	16
121	Systemic Administered mRNA as Therapy for Metabolic Diseases. *Trends in Molecular Medicine*, **2019**, 25, 3-5	11.5	2
120	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. *Haematologica*, **2019**, 104, 497-504	6.6	7
119	Porphyria and kidney diseases. *CKJ: Clinical Kidney Journal*, **2018**, 11, 191-197	4.5	24
118	Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. *New England Journal of Medicine*, **2018**, 378, 1479-1493	59.2	347
117	From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria. *Human Molecular Genetics*, **2018**, 27, 1164-1173	5.6	42
116	Urinary metabolic profiling of asymptomatic acute intermittent porphyria using a rule-mining-based algorithm. *Metabolomics*, **2018**, 14, 10	4.7	4
115	Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease. *Haematologica*, **2018**, 103, 587-596	6.6	12
114	Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients. *Critical Care*, **2018**, 22, 314	10.8	27
113	Characterization and origin of heme precursors in amniotic fluid: lessons from normal and pathological pregnancies. *Pediatric Research*, **2018**, 84, 80-84	3.2	1
112	High urinary ferritin reflects myoglobin iron evacuation in DMD patients. *Neuromuscular Disorders*, **2018**, 28, 564-571	2.9	6
111	Gene Therapy in a Patient with Sickle Cell Disease. *New England Journal of Medicine*, **2017**, 376, 848-855	59.2	418
110	Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from Gaucher disease model. *Haematologica*, **2017**, 102, 260-270	6.6	9
109	Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments. *Current Opinion in Hematology*, **2017**, 24, 198-207	3.3	19
108	Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. *European Journal of Heart Failure*, **2017**, 19, 1075-1076	12.3	20

107	Iloprost Use in Patients with Persistent Intestinal Ischemia Unsuitable for Revascularization. *Annals of Vascular Surgery*, **2017**, 42, 128-135	1.7	4
106	Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2017**, 1863, 428-439	6.9	11
105	A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1924-1932	12.7	35
104	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. *Anaesthesia, Critical Care & Pain Medicine*, **2017**, 36, 391-396	3	8
103	Mutation in human elevates levels of aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E8045-E8052	11.5	50
102	GNPAT polymorphism rs11558492 is not associated with increased severity in a large cohort of HFE p.Cys282Tyr homozygous patients. *Hepatology*, **2017**, 65, 1069-1071	11.2	3
101	Fecal calprotectin in inflammatory bowel diseases: update and perspectives. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 474-483	5.9	50
100	Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. *PLoS ONE*, **2017**, 12, e0172147	3.7	29
99	Hepcidin as a Major Component of Renal Antibacterial Defenses against Uropathogenic Escherichia coli. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 835-46	12.7	33
98	Reply. *Gastroenterology*, **2016**, 151, 771-2	13.3	2
97	Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans. *Gastroenterology*, **2016**, 150, 672-683.e4	13.3	61
96	Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene Therapy: Sustained Clinical Benefit in Severe Hemoglobinopathies. *Blood*, **2016**, 128, 2311-2311	2.2	3
95	Anémies microcytaires rares. *Bulletin De L'Academie Nationale De Medecine*, **2016**, 200, 335-347	0.1	
94	A Dominant Mutation in Mitochondrial Unfoldase CLPX Results in Erythropoietic Protoporphyria. *Blood*, **2016**, 128, 77-77	2.2	
93	Does IV Iron Induce Plasma Oxidative Stress in Critically Ill Patients? A Comparison With Healthy Volunteers. *Critical Care Medicine*, **2016**, 44, 521-30	1.4	8
92	Porphyrias: A 2015 update. *Clinics and Research in Hepatology and Gastroenterology*, **2015**, 39, 412-25	2.4	96
91	High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. *Kidney International*, **2015**, 88, 386-95	9.9	55
90	Mitochondrial energetic defects in muscle and brain of a Hmbs-/- mouse model of acute intermittent porphyria. *Human Molecular Genetics*, **2015**, 24, 5015-23	5.6	25

89	Human Erythroid 5-Aminolevulinate Synthase Mutations Associated with X-Linked Protoporphyria Disrupt the Conformational Equilibrium and Enhance Product Release. *Biochemistry*, **2015**, 54, 5617-31	3.2	16
88	LC-MS/MS method for hepcidin-25 measurement in human and mouse serum: clinical and research implications in iron disorders. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 1557-67	5.9	39
87	Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites. *Blood*, **2015**, 125, 534-41	2.2	25
86	Iron regulatory protein 1 sustains mitochondrial iron loading and function in frataxin deficiency. *Cell Metabolism*, **2015**, 21, 311-323	24.6	46
85	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. *Journal of Hepatology*, **2015**, 62, 848-54	13.4	157
84	Assessment of Cardiac Iron Overload in Chonically Transfused Patients with Thalassemia, Sickle Cell Anemia, and Myelodysplastic Syndromes. *Blood*, **2015**, 126, 2151-2151	2.2	
83	Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model. *International Journal of Biochemistry and Cell Biology*, **2014**, 51, 93-101	5.6	36
82	Urinary metabolic fingerprint of acute intermittent porphyria analyzed by (1)H NMR spectroscopy. *Analytical Chemistry*, **2014**, 86, 2166-74	7.8	16
81	Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells. *Biochimie*, **2014** , 106, 157-66	4.6	18
80	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. *EuPA Open Proteomics*, **2014**, 3, 60-67	0.1	18
79	Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria. *American Journal of Human Genetics*, **2014**, 94, 611-7	11	23
78	Les porphyries h□ditaires : anomalies du m□tabolisme de l□□me. *Bulletin De L'Academie Nationale De Medecine*, **2014**, 198, 1069-1093	0.1	
77	Erythropoietic Protoporphyric Red Blood Cells Are Resistant to the Growth of Malarial Parasites. *Blood*, **2014**, 124, 2670-2670	2.2	
76	Epistasis in iron metabolism: complex interactions between Cp, Mon1a, and Slc40a1 loci and tissue iron in mice. *Mammalian Genome*, **2013**, 24, 427-38	3.2	
75	Hepcidin regulates intrarenal iron handling at the distal nephron. *Kidney International*, **2013**, 84, 756-66	9.9	47
74	Heme Biosynthesis and Pathophysiology of Porphyrias. *Handbook of Porphyrin Science*, **2013**, 89-118	0.3	1
73	Late-onset X-linked dominant protoporphyria: an etiology of photosensitivity in the elderly. *Journal of Investigative Dermatology*, **2013**, 133, 1688-90	4.3	10
72	Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). *Human Molecular Genetics*, **2013**, 22, 1280-8	5.6	35

71	ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis. *Nature Genetics*, **2012**, 44, 170-3	36.3	108
70	A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. *British Journal of Dermatology*, **2012**, 167, 888-900	4	46
69	Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. *British Journal of Dermatology*, **2012**, 167, 901-13	4	53
68	Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. *Nature Genetics*, **2012**, 44, 174-7	36.3	93
67	An uncommon option for surviving bariatric surgery: regaining weight!. *American Journal of Medicine*, **2012**, 125, e1-2	2.4	4
66	Comprehensive cytochrome P450 CYP1A2 gene analysis in French caucasian patients with familial and sporadic porphyria cutanea tarda. *British Journal of Dermatology*, **2012**, 166, 425-9	4	6
65	Iron metabolism in patients with anorexia nervosa: elevated serum hepcidin concentrations in the absence of inflammation. *American Journal of Clinical Nutrition*, **2012**, 95, 548-54	7	24
64	Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. *Gastroenterology*, **2011**, 141, 1509-19, 1519.e1-3	13.3	32
63	Acute porphyric attack mimicking HIV-associated progressive polyradiculoneuropathy. *Médecine Et Maladies Infectieuses*, **2011**, 41, 441-3	4	1
62	ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. *Blood*, **2011**, 118, 1443-51	2.2	72
61	Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. *Human Mutation*, **2011**, 32, 590-7	4.7	45
60	A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma. *Journal of the European Academy of Dermatology and Venereology*, **2010**, 24, 1349-53	4.6	10
59	Iron regulatory proteins secure mitochondrial iron sufficiency and function. *Cell Metabolism*, **2010**, 12, 194-201	24.6	89
58	Porphyrias. *Lancet, The*, **2010**, 375, 924-37	40	506
57	Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. *Intensive Care Medicine*, **2010**, 36, 1044-8	14.5	70
56	Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of acute intermittent porphyria patients. *Journal of Internal Medicine*, **2009**, 266, 277-85	10.8	22
55	Erythropoietic protoporphyria. *Orphanet Journal of Rare Diseases*, **2009**, 4, 19	4.2	142
54	Melatonin and environmental lighting regulate ALA-S gene expression and So porphyrin biosynthesis in the rat harderian gland. *Chronobiology International*, **2008**, 25, 851-67	3.6	10

53	Sequential regulation of ferroportin expression after erythrophagocytosis in murine macrophages: early mRNA induction by haem, followed by iron-dependent protein expression. *Biochemical Journal*, **2008**, 411, 123-31	3.8	103
52	C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. *American Journal of Human Genetics*, **2008**, 83, 408-14	11	208
51	Genetic study of variation in normal mouse iron homeostasis reveals ceruloplasmin as an HFE-hemochromatosis modifier gene. *Gastroenterology*, **2007**, 132, 679-86	13.3	22
50	Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. *Blood*, **2007**, 109, 811-8	2.2	49
49	Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. *American Journal of Human Genetics*, **2006**, 78, 2-14	11	140
48	Biochemical compared to molecular diagnosis in acute intermittent porphyria. *Journal of Inherited Metabolic Disease*, **2006**, 29, 157-61	5.4	4
47	Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. *Biomedicine and Pharmacotherapy*, **2005**, 59, 20-4	7.5	43
46	A mouse model provides evidence that genetic background modulates anemia and liver injury in erythropoietic protoporphyria. *American Journal of Physiology - Renal Physiology*, **2005**, 288, G1208-16	5.1	25
45	Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria. *Human Molecular Genetics*, **2005**, 14, 3089-98	5.6	38
44	Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases. *British Journal of Cancer*, **2004**, 90, 1230-4	8.7	23
43	Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias. *Human Genetics*, **2004**, 114, 256-62	6.3	32
42	Analytical correlation between plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea. *Clinical Biochemistry*, **2004**, 37, 933-6	3.5	14
41	Acute Intermittent Porphyria: From Clinical to Molecular Aspects **2003**, 23-41		2
40	The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. *Nature Genetics*, **2002**, 30, 27-8	36.3	203
39	A molecular, enzymatic and clinical study in a family with hereditary coproporphyria. *Journal of Inherited Metabolic Disease*, **2002**, 25, 279-86	5.4	12
38	Ancestral founder of mutation W283X in the porphobilinogen deaminase gene among acute intermittent porphyria patients. *Human Heredity*, **2002**, 54, 69-81	1.1	13
37	Human hereditary hepatic porphyrias. *Clinica Chimica Acta*, **2002**, 325, 17-37	6.2	55
36	Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). *Cellular and Molecular Biology*, **2002**, 48, 33-41	1.1	7

35	Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria. *American Journal of Human Genetics*, **2001**, 68, 1130-8	11	48
34	Influence of Age and Gender on the Clinical Expression of Acute Intermittent Porphyria Based on Molecular Study of Porphobilinogen Deaminase Gene Among Swiss Patients. *Molecular Medicine*, **2001**, 7, 535-542	6.2	27
33	Identification of a prevalent nonsense mutation (W283X) and two novel mutations in the porphobilinogen deaminase gene of Swiss patients with acute intermittent porphyria. *Human Heredity*, **2000**, 50, 247-50	1.1	21
32	Porphobilinogen deaminase gene in African and Afro-Caribbean ethnic groups: mutations causing acute intermittent porphyria and specific intragenic polymorphisms. *Human Genetics*, **2000**, 107, 150-9	6.3	15
31	Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. *Journal of Hepatology*, **2000**, 32, 933-9	13.4	98
30	Inheritance in Erythropoietic Protoporphyria: A Common Wild-Type Ferrochelatase Allelic Variant With Low Expression Accounts for Clinical Manifestation. *Blood*, **1999**, 93, 2105-2110	2.2	114
29	Heme and acute inflammation role in vivo of heme in the hepatic expression of positive acute-phase reactants in rats. *FEBS Journal*, **1999**, 261, 190-6		18
28	Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. *American Journal of Human Genetics*, **1999**, 65, 984-94	11	90
27	Evaluation of mutation screening by heteroduplex analysis in acute intermittent porphyria: comparison with denaturing gradient gel electrophoresis. *Clinica Chimica Acta*, **1999**, 279, 133-43	6.2	13
26	New mutations of the hydroxymethylbilane synthase gene in German patients with acute intermittent porphyria. *Molecular and Cellular Probes*, **1999**, 13, 443-7	3.3	9
25	Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. *Hepatology*, **1998**, 27, 848-52	11.2	43
24	Exon 1 donor splice site mutations in the porphobilinogen deaminase gene in the non-erythroid variant form of acute intermittent porphyria. *Human Genetics*, **1998**, 103, 570-5	6.3	26
23	Mutations in the ferrochelatase gene of four Spanish patients with erythropoietic protoporphyria. *Journal of Investigative Dermatology*, **1998**, 111, 406-9	4.3	8
22	Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. *American Journal of Human Genetics*, **1998**, 62, 1341-52	11	117
21	Molecular characterization of homozygous variegate porphyria. *Human Molecular Genetics*, **1998**, 7, 1921-5	5.6	45
20	Molecular Characterization of Homozygous Variegate Porphyria. *Human Molecular Genetics*, **1998**, 7, 1921-1925	5.6	36
19	Acute hepatic porphyrias and primary liver cancer. *New England Journal of Medicine*, **1998**, 338, 1853-4	59.2	28
18	Nitric oxide synthase inhibition and the induction of cytochrome P-450 affect heme oxygenase-1 messenger RNA expression after partial hepatectomy and acute inflammation in rats. *Critical Care Medicine*, **1998**, 26, 1683-9	1.4	13

17	Molecular analysis of porphobilinogen (PBG) deaminase gene mutations in acute intermittent porphyria: first study in patients of Slavic origin. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1997**, 57, 217-24	2	15
16	Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria. *American Journal of Human Genetics*, **1997**, 60, 1373-83	11	122
15	Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. *Journal of Internal Medicine*, **1997**, 242, 213-7	10.8	75
14	Three novel mutations in the coproporphyrinogen oxidase gene. *Human Mutation*, **1997**, 9, 78-80	4.7	16
13	Protoporphyrinogen oxidase: complete genomic sequence and polymorphisms in the human gene. *Biochemical and Biophysical Research Communications*, **1996**, 226, 226-30	3.4	32
12	Detection of four novel mutations in the porphobilinogen deaminase gene in French Caucasian patients with acute intermittent porphyria. *Human Heredity*, **1996**, 46, 177-80	1.1	12
11	Review: molecular pathogenesis of hepatic acute porphyrias. *Journal of Gastroenterology and Hepatology (Australia)*, **1996**, 11, 1046-52	4	22
10	Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. *Human Molecular Genetics*, **1996**, 5, 407-10	5.6	42
9	Increased delta aminolevulinic acid and decreased pineal melatonin production. A common event in acute porphyria studies in the rat. *Journal of Clinical Investigation*, **1996**, 97, 104-10	15.9	35
8	Porphobilinogen deaminase gene structure and molecular defects. *Journal of Bioenergetics and Biomembranes*, **1995**, 27, 197-205	3.7	29
7	Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyria. *Journal of Bioenergetics and Biomembranes*, **1995**, 27, 215-9	3.7	16
6	Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. *Clinica Chimica Acta*, **1995**, 238, 163-8	6.2	45
5	Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks. *Life Sciences*, **1993**, 53, 621-7	6.8	45
4	Thyroid hormone extraction by plasma exchange: a study of extraction rate. *Biomedicine and Pharmacotherapy*, **1992**, 46, 413-7	7.5	7
3	Acc palustre et an hie h olytique potentiellement auto-immune chez un enfant dr anocytaire. *M decine Et Maladies Infectieuses*, **1992**, 22, 746-748	4	
2	Immunological specificity of monoclonal antibodies to Chlamydia psittaci ovine abortion strain. *Immunology Letters*, **1990**, 23, 217-21	4.1	2
1	Porphyria898-907		